News MSD opens $1bn plant for HPV vaccine in the US MSD has opened the doors of a $1bn facility at its site in Durham, North Carolina, that will be used to produce its HPV vaccine Gardasil.
R&D On incentivisation and investment in rare disease R&D To mark Rare Disease Day, pharmaphorum spoke with Paola Pozzi, partner of telethon strategy at Sofinnova Partners, about the outlook for investment in this field of research.
R&D Will 2025 be the year the pharmaceutical industry finds its ... After spending 2024 in recovery mode, the biopharma industry is finally showing signs of growth, climbing back toward its pre-pandemic heights.
Market Access The outlook for healthtech and life sciences in 2025 2024 was pivotal for UK Life Sciences’ venture funding landscape.
News Report says AZ's UK plant decision is not just about funding It's been reported that the UK government made an offer of £78 million in funding for AstraZeneca's abandoned £450 million vaccine facility in Speke.
News AstraZeneca abandons plan for £450m vaccine plant in UK In a shock move, AstraZeneca has ditched its plan to invest £450m in a new vaccine manufacturing plant in the UK.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
